MYL6B drives the capabilities of proliferation, invasion, and migration in rectal adenocarcinoma through the EMT process

Figures

• 

  Figure 1. MYL6B expression is upregulated in rectal adenocarcinoma and its overexpression could shorten survival of patients with rectal adenocarcinoma. (a) The mRNA levels of MYL6B in 65 cases of normal rectum and 65 cases of rectal adenocarcinoma, P = 1.75 × 10−40. (b) The expressional analysis of MYL6B in rectal adenocarcinoma obtained from the GEPIA website, P < 0.01. (c) UALCAN-TCGA database analysis of the MYL6B expression in rectal adenocarcinoma based on sample types (10 normal cases and 166 tumor samples), P < 0.01. (d) The comparison of overall survival between the groups with high and low expression of MYL6B, P = 0.022. (e) Quantitative analysis of MYL6B expression levels in different cell lines, **P < 0.01.

• 

  Figure 2. Detection of MYL6B knockdown efficiency in HCT116 and SW1116 cells. The interference of si-MYL6B reduced the MYL6B expression confirmed by the qRT-PCR method in (a) HCT116 and (d) SW1116 cells, **P < 0.01. The investigation of MYL6B knockdown efficiency through western blot analysis and quantification in (b and c) HCT116 and (e and f) SW1116 cells, **P < 0.01.

• 

  Figure 3. MYL6B knockdown suppressed cell proliferation, migration, and invasion of HCT116 and SW1116. (a and b) Cell proliferation was assessed by CCK-8 assay, **P < 0.01. (c and d) Results of transwell assays identified that cell migratory and invasive capabilities were blocked due to MYL6B knockdown, bar = 200 µm. The invasive and migratory cell numbers were quantified, **P < 0.01.

• 

  Figure 4. Downregulation of MYL6B induced cell apoptosis. Flow cytometry analyses were performed to assess the apoptotic ability of (a) HCT116 and (b) SW1116 cells, **P < 0.01.

• 

  Figure 5. Downregulation of MYL6B suppressed cell malignant behaviors via mediating the EMT process in rectal adenocarcinoma. Western blot results showed that E-cadherin expression was upregulated, while N-cadherin and Vimentin expression was attenuated in (a and b) HCT116 and (c and d) SW1116 cells after MYL6B knockdown, **P < 0.01.

• 

  Figure A1. Expression of MYL6B was determined using UALCAN-TCGA database based on (a) individual cancer stages, (b) gender, (c) age, (d) histological subtypes, and (e) nodal metastasis status.